Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 10/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567044 | 1.00 | TRPV4 (0.44) | TRPV4POLBBRS3KDM2BNR1I2 | |
| SCHEMBL25371215 | 0.85 | TRPV4 (0.43) | TRPV4BRS3 | |
| SCHEMBL30567053 | 0.85 | TRPV4 (0.43) | TRPV4BRS3 | |
| SCHEMBL31467621 | 0.85 | TRPV4 (0.39) | TRPV4POLBKDM4EGAAALDH1A1 | |
| SCHEMBL31467643 | 0.85 | CYP3A4 (0.47) | TRPV4POLBKDM4EALDH1A1CYP2D6 | |
| SCHEMBL31467641 | 0.85 | TRPV4 (0.41) | TRPV4BRS3GAAALDH1A1CYP2D6 | |
| SCHEMBL25370942 | 0.85 | TRPV4 (0.43) | TRPV4BRS3NR1I2KDM4E | |
| SCHEMBL25370662 | 0.84 | TRPV4 (0.40) | TRPV4BRS3NR1I2PDE5A | |
| SCHEMBL30567054 | 0.84 | TRPV4 (0.40) | TRPV4BRS3NR1I2PDE5A | |
| SCHEMBL26065980 | 0.84 | POLB (0.54) | TRPV4POLBKDM2BKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | claimed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | claimed |
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023164063-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171463-A1 | EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF | EBPL, EBP, CREBBP | TRPV4 4535/4885POLB 1161/4885BRS3 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.